Insulet Corporation with ticker code (PODD) now have 19 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $270.00 and $163.00 suggesting an average Analsyt target price of $232.17. Given that the stocks previous close was at $197.87 this would indicate that there is a potential upside of 17.3%. Also worth taking note is the 50 day moving average now sits at $184.41 and the 200 day moving average is $234.73. The company has a market cap of 14.14B. The stock price for the company is currently $202.43 USD
The potential market cap would be $16,585,483,208 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 117.69, revenue per share of $22.35 and a 2.36% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
